CohBar

CohBar, Inc. engages in the research and development of mitochondria-based therapeutics. It focuses on treatments of diseases, which include diabetes, obesity, fatty liver disease and non-alcoholic steatohepatitis, cancer, Alzheimer's disease, and atherosclerosis. The company was founded by Nir Barzilai, Pinchas Cohen, David Sinclair, John Amatruda, and Laura Cobb on October 19, 2007 and is headquartered in Menlo Park, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CohBar, Inc. is a clinical stage biotechnology company, which engages in the research and development of mitochondria-based therapeutics targeting chronic and age-related diseases. The company was founded by Nir Barzilai, Pinchas Cohen, David Sinclair, John Amatruda, and Laura Cobb on October 19, 2007 and is headquartered in Menlo Park, CA.

MENLO PARK, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced topline results from the multi-center, randomized, double-blind, placebo-controlled Phase 1a/1b clinical study of CB4211, under development for nonalcoholic steatohepatitis (NASH) and obesity. The study met its primary endpoint showing that CB4211 was well-tolerated and appeared safe with no serious adverse events. Evaluation of the exploratory pharmacodynamic endpoints from the Phase 1b stage of the study comparing CB4211 to placebo demonstrated robust and significant reductions in key biomarkers of liver damage, ALT and AST, a significant decrease in glucose levels, and a trend towards lower body weight after four weeks of treatment. Both the CB4211 and placebo groups had substantial reductions in liver fat content compared to baseline.

CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity

CohBar Inc (NASDAQ: CWBR) has updated the timing for releasing Phase 1a/1b trial data of CB4211 for the potential treatment of nonalcoholic steatohepatitis (NASH) and obesity.  The process of data entry and final validation, which must be concluded before database lock, is ongoing.

CohBar Stock Slumps As Data From NASH, Obesity Candidate Delayed By Almost Two Months

MENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced an update on the timing for the release of the data for its Phase 1a/1b clinical study of CB4211 for the potential treatment of nonalcoholic steatohepatitis and obesity. The process of data entry and final validation by the company's clinical research organization, which must be concluded prior to database lock, is ongoing. Once the database is locked, external biostatisticians will have access to the unblinded data from the study, enabling them to perform the data analysis and generate the final output. Only after this process is complete will the data be provided to the company. The company currently expects to release topline data prior to Labor Day 2021.

CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity

MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced its Chief Executive Officer Dr. Joseph Sarret will present a corporate overview at the BIO 2021 Digital Conference, to be held on June 14 - 18, 2021. This presentation will be available on demand for registered attendees.

CohBar to Present at the BIO 2021 Digital Conference

CohBar, Inc. (CWBR) CEO Joe Sarret on Q1 2021 Results - Earnings Call Transcript

Company to host conference call at 5:00 p.m. ET Company to host conference call at 5:00 p.m. ET

CohBar Reports First Quarter 2021 Financial Results and Provides Business Update

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021

Announces change to the Board of Director's Chair Announces change to the Board of Director's Chair

CohBar Appoints Joseph J. Sarret, M.D.

CohBar, Inc. is an interesting early-clinical-stage biotechnology company developing mitochondrial-based therapeutics for treating chronic and age-related diseases including nonalcoholic steatohepatitis and obesity, amongst others. CohBar's pipeline consists of the lead compound, CB4211, which is in a Phase 1b and Phase 1a/1b for NASH and Obesity, respectively, and four other pre-clinical mitochondrial-based programs.

CohBar: A Promising Early Pureplay On Mitochondrial-Based Therapeutics

MENLO PARK, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that the last subject has completed their final visit in the Phase 1b stage of the CB4211 clinical study for nonalcoholic steatohepatitis (NASH) and obesity. The company currently expects to release topline data in early July 2021.

CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity

MENLO PARK, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer Steven Engle will present at the Mitochondria-Targeted Drug Development Summit being held virtually on April 27 - 29, 2021. This summit is an industry-led meeting focused on developing therapies targeting mitochondrial dysfunction for age-related and mitochondria diseases.

CohBar to Present at the Mitochondria-Targeted Drug Development Summit

CohBar, Inc. (CWBR) CEO Steve Engle on Q4 2020 Results - Earnings Call Transcript

CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update

MENLO PARK, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the completion of enrollment in the Phase 1b stage of the CB4211 clinical study for nonalcoholic steatohepatitis (NASH) and obesity. The company currently expects topline data at the end of the second quarter based on projected timing of the last subject visit and other factors. The company plans to announce the completion of the last subject visit, which is currently anticipated in April 2021. For more information, please join the company's quarterly call on March 30, 2021 at 5:00pm ET/2:00pm PT.

CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity

CohBar to Announce 2020 Fourth Quarter Financial Results and Provide Business Update on March 30, 2021

MENLO PARK, Calif., March 12, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that CEO Steven Engle will participate in a fireside chat with Research Analyst Jason McCarthy at the Inaugural Emerging Growth Conference presented by M Vest LLC and Maxim Group LLC. Mr. Engle will also present a company overview, which will be available on demand. The conference will be held virtually March 17 – 19, 2021.

CohBar to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

MENLO PARK, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will participate in a fireside chat with ROTH Senior Research Analyst Elemer Piros, Ph.D. at the 33rd Annual ROTH Conference, being held virtually March 15 – 17, 2021.

CohBar to Present at the 33rd Annual ROTH Conference

MENLO PARK, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company overview at the BIO CEO & Investor Digital Conference, being held virtually on February 16 - 18, 2021. This presentation will be available on demand for registered attendees.

CohBar to Present at the BIO CEO & Investor Digital Conference

MENLO PARK, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company overview at the 3rd Annual Longevity Therapeutics Conference, being held virtually on January 26 - 28, 2021. This presentation will be available for registered attendees at 12:15PM PT on Thursday, January 28, 2021.

CohBar to Present at the 3rd Annual Longevity Therapeutics Conference

MENLO PARK, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced new preclinical data confirming the efficacy of its apelin agonist peptides in a preclinical model of acute respiratory distress syndrome (ARDS). The company expects the apelin agonists to have potential to treat COVID-19 associated ARDS as well as ARDS patients in general, of which there are approximately three million globally.

CohBar Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome (ARDS) Model

MENLO PARK, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company overview at the Piper Sandler 32nd Annual Healthcare Conference, being held virtually on December 1 - 3, 2020. This presentation will be available on demand for registered attendees.

CohBar to Present at the Piper Sandler 32nd Annual Healthcare Conference

CohBar, Inc. (CWBR) CEO Steve Engle on Q3 2020 Results - Earnings Call Transcript

CohBar Reports Third Quarter 2020 Financial Results and Provides Business Update

CohBar to Announce 2020 Third Quarter Financial Results and Provide Business Update on November 16, 2020

MENLO PARK, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced it will host a Key Opinion Leader (KOL) webinar on the current treatment landscape in idiopathic pulmonary fibrosis (IPF), the unmet medical need, and positive findings from preclinical studies of its CB5138 Analogs on Friday, November 6 at 2:00pm ET.

News for CohBar Stock (CWBR)